ALIGOS THERAPEUTICS INC (ALGS) Stock Income Statement
NASDAQ:ALGS - Nasdaq - US01626L2043 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.27M | 3.94M | 15.53M | 13.91M | 4.36M | |||
| Operating Expenses | 85.42M | 88.90M | 97.86M | 111.49M | 132.68M | |||
| Research and Development | 68.41M | 70.27M | 73.04M | 85.08M | 104.15M | |||
| Selling, General, and Administrative Expenses | 17.02M | 18.63M | 24.82M | 26.41M | 28.53M | |||
| Operating Income | -82.15M | -84.95M | -82.33M | -97.58M | -128.32M | |||
| Interest Income/Expense | 1.93M | 1.67M | 4.30M | 1.52M | 240.00K | |||
| Other Income/Expense | 31.51M | -43.40M | -3.05M | 120.00K | -110.00K | |||
| Non Recurring Items | N/A | -4.20M | -5.80M | N/A | N/A | |||
| Income Before Taxes | -52.91M | -130.88M | -86.88M | -95.94M | -128.19M | |||
| Income Tax | 350.00K | 331.00K | 795.00K | 110.00K | 140.00K | |||
| Net Income | -53.26M | -131.21M | -87.68M | -96.05M | -128.33M | |||
| EBITDA | -81.21M | -83.93M | -80.77M | -95.27M | -125.30M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -10.39 | -20.94 | -34.11 | -2.25 | -3.22 | |||
| Non GAAP EPS | -7.78 | -11.17 | -39.75 | -56.50 | -80.00 | |||
| Statistics | ||||||||
| Profit Margin | -1628.75% | -3326.01% | -564.61% | -690.51% | -2943.35% | |||
| Operating Profit Margin | -2512.26% | -2153.46% | -530.15% | -701.51% | -2943.12% | |||
All data in USD